Update on Acquisition of Lyramid Limited

RNS Number : 2223S

Roquefort Investments PLC

12 November 2021

 

12 November 2021

Roquefort Investments plc

("Roquefort Investments" or the "Company")

Update on Acquisition of Lyramid Limited

Roquefort Investments (LSE:ROQ), the London listed investment company established to acquire businesses focused on early-stage opportunities in the medical biotechnology sector , is pleased to announce that it has commenced marketing to potential investors to fund the acquisition and pre-clinical drug development programme of Lyramid Limited, details of which were announced on 29 September 2021.  A copy of the presentation is available on the Company's website at https://www.roquefortinvest.com/presentations

The Company looks forward to providing further updates in relation to the acquisition of Lyramid Limited as and when appropriate.

The Company's shares remain suspended from trading on the Main Market of the London Stock Exchange pending the publication of a Prospectus setting out full details of the potential transaction.

 

Enquiries:

Roquefort Investments plc
Stephen West (Chairman)	[phone]
Optiva Securities Limited (Joint Broker)
Christian Dennis	[phone]

For further information, please visit www.roquefortinvest.com and @roquefortinvest on Twitter.

LEI: ‎254900P4SISIWOR9RH34

 

END

 

 

ACQBTBRTMTTBMLB